NCT01999985 - Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 21, 2017

Study Completion Date

May 30, 2019

Conditions

Lung CancerNon-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Dasatinib - 1A

1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.

DRUG

Afatinib - 1A

1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.

DRUG

Dasatinib - 1B

In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.

DRUG

Afatinib - 1B

In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa